OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $9.64 -0.14 (-1.43%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Astellas Pharma Stock (OTCMKTS:ALPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astellas Pharma alerts:Sign Up Key Stats Today's Range$9.63▼$10.0250-Day Range$8.84▼$10.1552-Week Range$8.37▼$13.14Volume103,862 shsAverage Volume205,634 shsMarket Capitalization$17.45 billionP/E RatioN/ADividend Yield3.42%Price TargetN/AConsensus RatingN/A Company OverviewAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Read More… Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Stock News HeadlinesAstellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and CaregiversMay 28 at 10:00 AM | prnewswire.comAstellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna BioMay 21, 2025 | prnewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)Astellas CEO Says Engaging With Activist Investor FarallonMay 7, 2025 | bloomberg.comAstellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual CongressesMay 1, 2025 | prnewswire.comAstellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call TranscriptApril 28, 2025 | seekingalpha.comAstellas Pharma and JFCR partner for oncology researchApril 3, 2025 | msn.comSinglera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT MeetingMarch 24, 2025 | globenewswire.comSee More Headlines ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $9.66 at the beginning of the year. Since then, ALPMY shares have decreased by 0.2% and is now trading at $9.64. View the best growth stocks for 2025 here. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings results on Friday, April, 25th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.12. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a positive trailing twelve-month return on equity of 13.69% and a negative net margin of 3.10%. When did Astellas Pharma's stock split? Astellas Pharma shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/25/2025Today5/28/2025Next Earnings (Estimated)8/07/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,754Year Founded1923Profitability EPS (Most Recent Fiscal Year)$0.17 Trailing P/E RatioN/A Forward P/E Ratio23.29 P/E GrowthN/ANet Income$113 million Net Margins-3.10% Pretax MarginN/A Return on Equity13.69% Return on Assets6.06% Debt Debt-to-Equity Ratio0.39 Current Ratio1.04 Quick Ratio0.80 Sales & Book Value Annual Sales$11.11 billion Price / Sales1.59 Cash Flow$1.16 per share Price / Cash Flow8.42 Book Value$5.84 per share Price / Book1.67Miscellaneous Outstanding Shares1,809,660,000Free FloatN/AMarket Cap$17.70 billion OptionableNot Optionable Beta0.27 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:ALPMY) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.